Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term results of dose density therapy in patients with aggressive lymphoma.
Fridrik MA, Hausmaninger H, Linkesch W, Greil R, Krieger O, Baldinger C, Klocker J, Pont J, Oberaigner W. Fridrik MA, et al. Among authors: krieger o. Ann Hematol. 2005 Apr;84(4):217-22. doi: 10.1007/s00277-004-0936-x. Epub 2004 Nov 6. Ann Hematol. 2005. PMID: 15538568 Clinical Trial.
Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B. Nachbaur D, et al. Among authors: krieger o. Ann Hematol. 2005 Jul;84(7):462-73. doi: 10.1007/s00277-004-1003-3. Epub 2005 Feb 23. Ann Hematol. 2005. PMID: 15726362
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R. Fridrik MA, et al. Among authors: krieger o. Ann Hematol. 2010 Mar;89(3):273-82. doi: 10.1007/s00277-009-0811-x. Epub 2009 Aug 20. Ann Hematol. 2010. PMID: 19693500 Clinical Trial.
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stöger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T. Fridrik MA, et al. Among authors: krieger o. Ann Hematol. 1997 Oct;75(4):135-40. doi: 10.1007/s002770050330. Ann Hematol. 1997. PMID: 9402845 Clinical Trial.
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, Greil R. Fridrik MA, et al. Among authors: krieger o. Eur J Cancer. 2016 May;58:112-21. doi: 10.1016/j.ejca.2016.02.004. Epub 2016 Mar 15. Eur J Cancer. 2016. PMID: 26990931 Clinical Trial.
Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.
Fridrik MA, Jäger G, Kienzer HR, Hausmaninger H, Oppitz P, Krieger O, Zabernigg A, Lang A, Neubauer M, Weidinger G, Schiller L, Seewann HL, Chott A, Linkesch W. Fridrik MA, et al. Among authors: krieger o. Eur J Cancer. 1998 Sep;34(10):1560-4. doi: 10.1016/s0959-8049(98)00140-3. Eur J Cancer. 1998. PMID: 9893628 Clinical Trial.
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J. Hilbe W, et al. Among authors: krieger o. Leuk Lymphoma. 2001 Nov-Dec;42(6):1283-8. doi: 10.3109/10428190109097753. Leuk Lymphoma. 2001. PMID: 11911409 Clinical Trial.
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group. Kühr T, et al. Among authors: krieger o. Leuk Res. 2003 May;27(5):405-11. doi: 10.1016/s0145-2126(02)00223-0. Leuk Res. 2003. PMID: 12620292 Clinical Trial.
Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry.
Greinix HT, Nachbaur D, Krieger O, Eibl M, Knöbl P, Kalhs P, Lutz D, Linkesch W, Niederwieser D, Hinterberger W, Lechner K, Rosenmayr A, Gritsch B. Greinix HT, et al. Among authors: krieger o. Br J Haematol. 2002 Jun;117(4):914-23. doi: 10.1046/j.1365-2141.2002.03532.x. Br J Haematol. 2002. PMID: 12060131 Free article.
88 results